Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 43Rectal Neoplasms 12Colonic Neoplasms 12Neoplasm Metastasis 6Stomach Neoplasms 5Pancreatic Neoplasms 5Gallbladder Neoplasms 3Colorectal Cancer Metastatic 3Cholangiocarcinoma 3Neutropenia 2Neoplasms 2Bile Duct Neoplasms 2Adenocarcinoma 2mCRC 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumor 1Recurrence 1Pretreated Metastatic Colorectal Cancer 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Nasopharyngeal Carcinoma 1Microsatellite-stable Colorectal Cancer 1Metastatic Gastric Adenocarcinoma 1High-grade Extra Pulmonary Neuroendocrine Cancer 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Gastric and Gastroesophageal Junction Adenocarcinoma 1Gastric Cancer Adenocarcinoma Metastatic 1Gastric Adenocarcinoma 1

Interventions

camrelizumab 2apatinib 2trifluridine tipiracil drug combination 1tipiracil 1irinotecan sucrosofate 1Trifluridine 1S 1 (combination) 1Ramucirumab 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Metastatic Gastric Adenocarcinoma × trifluridine tipiracil drug combination × Clear all
NCT05927857 2026-04-09

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

National Health Research Institutes, Taiwan

Phase 1/2 Recruiting
45 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡